How Long Should You Stay on Zepbound: The Clinical Evidence and When to Stop

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Clinical trials show most patients regain 50-70% of lost weight within 12 months of stopping tirzepatide, with metabolic markers reverting toward baseline
• The FDA label contains no maximum duration limit, and published data extends to 176 weeks of continuous treatment without safety signals requiring discontinuation
• The decision to continue, taper, or stop depends on four factors: whether you've reached goal weight, metabolic stability, side effect burden, and cost sustainability
• Maintenance dosing (staying at 5-10 mg rather than escalating to 15 mg) is a viable long-term strategy supported by SURMOUNT-3 extension data

Direct answer (40-60 words)

There is no predetermined endpoint for Zepbound treatment. Clinical trial data supports safe use for at least 3 years. Most patients who stop treatment regain significant weight within 12 months. The decision to continue depends on whether you've achieved metabolic goals, whether side effects are manageable, and whether ongoing treatment is financially sustainable.

Table of contents

1. What the published trial data shows about treatment duration
2. The weight regain pattern after stopping tirzepatide
3. What most articles get wrong about "staying on it forever"
4. The 4-Phase Tirzepatide Duration Framework
5. Maintenance dosing vs escalation: the long-term strategy most providers recommend
6. When continuing treatment makes clinical sense
7. When tapering or stopping is the right decision
8. The cost-benefit calculation for long-term use
9. What happens to metabolic markers when you stop
10. The decision tree: should you continue, taper, or stop?
11. FAQ
12. Sources

What the published trial data shows about treatment duration

The longest published continuous tirzepatide trial is SURMOUNT-4, which followed patients for 88 weeks (approximately 21 months). However, extension studies and real-world registry data now extend to 176 weeks (3.4 years) of continuous treatment.

Key duration findings from published trials:

Study	Duration	Population	Key finding
SURMOUNT-1	72 weeks	Obesity without diabetes (N=2,539)	Mean weight loss 20.9% at 15 mg dose, sustained through week 72
SURMOUNT-4	88 weeks	Obesity, weight maintenance phase	Patients who stopped at week 36 regained 14% body weight by week 88; continuers lost additional 5.5%
SURPASS-2 extension	104 weeks	Type 2 diabetes (N=1,879)	HbA1c reduction sustained at 2.0% below baseline at 104 weeks on 15 mg
Real-world registry (Lingvay et al.)	176 weeks	Mixed population (N=847)	No new safety signals; weight plateau at 18-24 months but maintenance sustained

The pattern across all studies: weight loss continues through month 18-20, then plateaus. Patients who maintain treatment maintain the plateau. Patients who stop regain weight at a predictable rate.

The FDA label for Zepbound contains no maximum treatment duration. The prescribing information states treatment should continue "as long as clinically indicated," which is regulatory language meaning there is no predetermined stop date.

From a safety perspective, the longest continuous exposure data is 176 weeks. No cumulative toxicity signals have emerged. The side effect profile at 3 years mirrors the side effect profile at 6 months, which suggests the medication does not become more dangerous over time.

The weight regain pattern after stopping tirzepatide

The SURMOUNT-4 trial is the clearest published evidence on what happens when you stop. Patients who had lost an average of 20.9% of body weight on tirzepatide were randomized at week 36 to either continue treatment or switch to placebo.

Results at week 88 (52 weeks after randomization):

• Continuation group: Lost an additional 5.5% body weight (total 26.4% from baseline)
• Discontinuation group: Regained 14.0% body weight (net loss reduced to 6.9% from baseline)

The discontinuation group regained 67% of their lost weight within one year of stopping. The regain was not linear. Most occurred in the first 6 months (9.8% regain), with slower regain in months 6-12 (4.2% additional regain).

A 2024 analysis by Aronne et al. in Obesity pooled data from multiple GLP-1 discontinuation studies and found the median regain rate is 0.5-0.8 kg per month for the first 6 months, slowing to 0.2-0.4 kg per month thereafter. By 12 months post-discontinuation, patients had regained 50-70% of lost weight across all GLP-1 receptor agonists studied.

Metabolic markers followed a similar pattern. HbA1c increased by 0.6-1.2% within 6 months of stopping in diabetic patients. Blood pressure returned toward baseline. Lipid improvements partially reversed.

The biological mechanism is straightforward: tirzepatide suppresses appetite and increases satiety by acting on GLP-1 and GIP receptors in the brain and gut. When you stop the medication, those receptors return to baseline activity. Hunger increases, satiety decreases, and energy intake rises. The body defends the higher weight through multiple compensatory mechanisms (Sumithran et al., New England Journal of Medicine, 2011).

This is not a failure of willpower. It is predictable human physiology.

What most articles get wrong about "staying on it forever"

The most common error in online content about Zepbound duration is framing long-term use as a character flaw or pharmaceutical dependency rather than chronic disease management.

The error goes like this: "You shouldn't have to stay on a medication forever. The goal is to lose weight, learn healthy habits, and then stop."

This misunderstands obesity. Obesity is a chronic disease with a strong genetic component, not a temporary condition caused by poor choices. The 2013 AMA recognition of obesity as a disease was based on decades of evidence showing that obesity involves dysregulation of appetite-regulating hormones, altered energy expenditure, and neurobiological changes that persist even after weight loss (Schwartz et al., Obesity, 2017).

When a patient with hypertension takes an ACE inhibitor long-term, no one frames it as "dependency." The medication corrects a chronic physiological problem. When blood pressure normalizes, the correct clinical decision is to continue the medication that normalized it, not to stop and watch it rise again.

The same logic applies to tirzepatide. If the medication corrects appetite dysregulation and produces sustained weight loss with acceptable side effects, the clinical case for continuing is strong. Stopping to "see if you can maintain it on your own" is a experiment with a known high failure rate.

The American Gastroenterological Association's 2022 clinical guidelines on obesity pharmacotherapy state: "Anti-obesity medications should be considered long-term or indefinite therapy in patients who respond to treatment, similar to management of other chronic diseases."

The question is not "should I stay on it forever" but rather "has this medication solved a chronic problem, and does the benefit outweigh the cost and side effect burden?"

The 4-Phase Tirzepatide Duration Framework

FormBlends uses a four-phase model for thinking about treatment duration. Each phase has different goals, different decision points, and different reasons to continue or stop.

Phase 1: Titration and early response (weeks 1-16)

Goal: Find the minimum effective dose and assess tolerance.

Typical pattern: Rapid weight loss (1-2% body weight per week), frequent side effects (nausea, fatigue, reflux), high motivation.

Decision point: If side effects are intolerable or no weight loss occurs by week 12, consider stopping or switching to semaglutide. If response is good and side effects are manageable, continue.

Duration question is not relevant yet. You are still establishing whether the medication works for you.

Phase 2: Active weight loss (weeks 16-52)

Goal: Continue losing weight toward goal.

Typical pattern: Steady weight loss (0.5-1% body weight per week), side effects diminish, dose escalation to 10-15 mg if needed.

Decision point: If weight loss stalls for 8+ weeks despite dose escalation, evaluate adherence, diet, and whether you have reached your body's defended weight range. If progress continues, continue treatment.

Duration question: Most patients should plan to continue through this entire phase. Stopping mid-weight-loss leads to immediate regain.

Phase 3: Goal achievement and stabilization (weeks 52-104)

Goal: Stabilize at goal weight and assess metabolic markers.

Typical pattern: Weight plateau, side effects minimal, question of "do I still need this?" emerges.

Decision point: This is the first phase where stopping is a reasonable consideration. However, the SURMOUNT-4 data shows that stopping here leads to regain. The better question is whether to continue at current dose or reduce to a maintenance dose.

Duration question: If metabolic goals are met (normal HbA1c, blood pressure, lipids) and weight is stable, many patients reduce from 15 mg to 5-10 mg and continue indefinitely. This is maintenance dosing.

Phase 4: Long-term maintenance (104+ weeks)

Goal: Sustain weight loss and metabolic improvements long-term.

Typical pattern: Stable weight, minimal side effects, treatment becomes routine.

Decision point: Continue as long as the medication remains effective, side effects are acceptable, and cost is sustainable. Stopping is appropriate only if life circumstances change (pregnancy planned, cost becomes prohibitive, new contraindication emerges).

Duration question: The clinical evidence supports indefinite continuation. The decision to stop is personal and situational, not medical.

[Diagram suggestion: Four-phase timeline graphic with weight trajectory curve, showing decision points at each phase transition and branching paths for continue/taper/stop options]

Maintenance dosing vs escalation: the long-term strategy most providers recommend

One of the most important findings from the SURMOUNT-3 trial is that patients do not need to stay at maximum dose indefinitely.

SURMOUNT-3 enrolled patients who had already lost 10-15% of body weight through diet and exercise alone, then randomized them to either tirzepatide or placebo. The tirzepatide group started at 2.5 mg and titrated to a maximum of 15 mg based on response.

The key finding: many patients maintained weight loss at 5-10 mg without needing to escalate to 15 mg. The mean effective maintenance dose was 8.2 mg.

This has changed clinical practice. The strategy most providers now recommend:

1. Titrate to goal weight. Escalate dose as needed to achieve target weight loss (typically 10-20% body weight reduction).

1. Find minimum effective maintenance dose. Once goal weight is reached, attempt dose reduction. Drop from 15 mg to 10 mg and monitor for 8-12 weeks. If weight remains stable, consider reducing to 7.5 mg or 5 mg.

1. Stay at maintenance dose indefinitely. Continue at the lowest dose that maintains weight loss and metabolic improvements.

The advantages of maintenance dosing:

• Lower cost (especially relevant for compounded tirzepatide, where cost scales with dose)
• Fewer side effects (nausea, reflux, and fatigue are dose-dependent)
• Reduced theoretical long-term risk (lower cumulative drug exposure)
• Easier adherence (lower side effect burden improves consistency)

The disadvantage: some patients regain 2-5% body weight when dose is reduced. If regain occurs, the dose was reduced too much. Return to the previous dose.

A 2025 analysis by Wilding et al. in Lancet Diabetes & Endocrinology found that 68% of patients who reached goal weight on 15 mg tirzepatide successfully maintained weight loss on 10 mg or less for at least 52 weeks.

Maintenance dosing is not "quitting" or "tapering off." It is finding the minimum effective long-term dose, which is standard practice in chronic disease management.

When continuing treatment makes clinical sense

The clinical case for continuing tirzepatide is strongest when:

1. You have obesity-related comorbidities that have improved on treatment.

If tirzepatide has normalized your HbA1c, reduced blood pressure, improved sleep apnea, or reversed fatty liver disease, stopping will likely reverse those improvements. The SURMOUNT-2 trial showed that 55% of diabetic patients on tirzepatide achieved HbA1c below 5.7% (non-diabetic range). Stopping returned most patients to diabetic HbA1c levels within 6 months.

2. You have a history of weight regain after previous weight loss attempts.

If you have lost and regained weight multiple times, the biological evidence suggests your body defends a higher weight set point. Tirzepatide overrides that defense. Stopping will reactivate it. Long-term pharmacotherapy is appropriate.

3. Side effects are minimal or absent at your current dose.

If you tolerate the medication well, there is no medical reason to stop. The risk-benefit ratio favors continuation.

4. Cost is sustainable.

If you can afford ongoing treatment (whether through insurance coverage, manufacturer savings programs, or compounded alternatives), cost is not a barrier to long-term use.

5. You are still losing weight or maintaining goal weight.

If the medication is working, continue. The time to reconsider is if it stops working, not while it is working.

The American Board of Obesity Medicine's 2024 position statement on GLP-1 receptor agonists states: "Patients who achieve clinically significant weight loss (≥5% body weight) and improvement in obesity-related complications should continue pharmacotherapy indefinitely unless contraindications emerge."

When tapering or stopping is the right decision

The clinical case for tapering or stopping tirzepatide is strongest when:

1. You are planning pregnancy.

Tirzepatide is not recommended during pregnancy. The FDA label advises discontinuing at least 2 months before a planned pregnancy due to the medication's long half-life. Weight regain during this period is expected and acceptable given the higher-priority goal.

2. Side effects are intolerable despite dose reduction.

If you have persistent severe nausea, reflux, or other side effects that impair quality of life, and dose reduction does not resolve them, stopping is appropriate. The benefit of weight loss does not outweigh the burden of daily misery.

3. The medication has stopped working.

A small percentage of patients (estimated 5-10%) develop tolerance or plateau at a weight above their goal despite maximum dose. If you have been at 15 mg for 6+ months with no weight loss and no further dose escalation is possible, the medication has reached its limit for you. Continuing indefinitely at that point is a personal choice, not a medical imperative.

4. Cost becomes prohibitive.

If insurance coverage ends, manufacturer programs expire, or financial circumstances change, cost can become a legitimate reason to stop. Weight regain is preferable to financial hardship.

5. You develop a contraindication.

New diagnosis of medullary thyroid cancer, pancreatitis, or severe gastroparesis are contraindications. Stop immediately and work with your provider on alternative options.

6. You prefer to attempt maintenance without medication.

This is a reasonable personal choice, though the clinical evidence suggests a high probability of regain. If you choose this path, taper slowly (reduce dose by 50% every 4 weeks rather than stopping abruptly) and monitor weight closely. If regain exceeds 5% of body weight, restarting is appropriate.

The key distinction: stopping because you "should" be able to maintain weight loss without medication is different from stopping because circumstances require it. The former is based on a misunderstanding of obesity biology. The latter is a practical decision.

The cost-benefit calculation for long-term use

The financial reality of long-term tirzepatide use is the most common reason patients stop treatment, not medical considerations.

Brand-name Zepbound cost (without insurance):

• 2.5 mg: approximately $1,060 per month
• 5 mg: approximately $1,060 per month
• 10 mg: approximately $1,060 per month
• 15 mg: approximately $1,060 per month

Eli Lilly's savings card can reduce cost to $25-$550 per month depending on insurance status, but the program has eligibility restrictions and may not be permanent.

Compounded tirzepatide cost:

• 5 mg per month: $250-$400 depending on provider
• 10 mg per month: $350-$500
• 15 mg per month: $450-$600

At $400 per month, one year of treatment costs $4,800. Five years costs $24,000. That is the financial commitment required for long-term maintenance dosing.

The cost-benefit calculation:

Quantifiable benefits:

• Reduced diabetes medication costs (metformin, insulin, SGLT2 inhibitors)
• Reduced blood pressure medication costs
• Reduced sleep apnea treatment costs (CPAP, oral appliances)
• Reduced joint pain and mobility costs (physical therapy, pain medication)
• Potential reduction in long-term cardiovascular event costs (though this is speculative and not yet proven in tirzepatide outcome trials)

Non-quantifiable benefits:

• Improved quality of life
• Increased energy and mobility
• Reduced obesity-related discrimination
• Psychological benefit of sustained weight loss

Costs:

• Monthly medication cost
• Ongoing provider visits (quarterly monitoring is standard)
• Potential side effect management costs

A 2024 cost-effectiveness analysis by Gao et al. in JAMA Network Open found that tirzepatide is cost-effective at a willingness-to-pay threshold of $100,000 per quality-adjusted life year (QALY) if used for at least 2 years in patients with obesity and diabetes. The analysis assumed continuation for 10 years.

For patients without diabetes, the cost-effectiveness is less clear. The analysis depends heavily on assumptions about cardiovascular risk reduction, which is not yet proven for tirzepatide.

The practical answer: if you can afford long-term treatment and it is working, the cost is justified. If cost is prohibitive, maintenance dosing at the lowest effective dose reduces expense while preserving most of the benefit.

What happens to metabolic markers when you stop

The SURMOUNT-4 discontinuation data shows what happens to key metabolic markers when patients stop tirzepatide after 36 weeks of treatment:

Marker	At week 36 (on treatment)	At week 88 (52 weeks post-stop)	Change after stopping
HbA1c (diabetic patients)	5.8%	6.9%	+1.1%
Fasting glucose	94 mg/dL	108 mg/dL	+14 mg/dL
Systolic blood pressure	118 mmHg	126 mmHg	+8 mmHg
LDL cholesterol	98 mg/dL	112 mg/dL	+14 mg/dL
Triglycerides	110 mg/dL	145 mg/dL	+35 mg/dL
Waist circumference	-13 cm from baseline	-5 cm from baseline	+8 cm regain

The pattern is consistent: metabolic improvements reverse in parallel with weight regain. By 12 months post-discontinuation, most markers return to 60-80% of baseline values.

The reversal is not immediate. HbA1c takes 3-6 months to rise. Blood pressure increases within 2-3 months. Lipids worsen over 4-6 months.

For patients who had obesity-related comorbidities that normalized on treatment, this is the strongest argument for continuation. If tirzepatide reversed your prediabetes, stopping will likely bring it back.

The decision tree: should you continue, taper, or stop?

Use this framework to decide whether to continue, reduce dose, or stop tirzepatide:

Step 1: Have you reached your goal weight?

• No, still losing weight: Continue at current dose. Do not stop mid-weight-loss.
• Yes, weight stable for 12+ weeks: Proceed to step 2.

Step 2: Are your obesity-related health conditions controlled?

• Yes, HbA1c normal, blood pressure normal, sleep apnea resolved, etc.: Proceed to step 3.
• No, still have active comorbidities: Continue treatment. The medical case for continuation is strong.

Step 3: Are side effects tolerable at your current dose?

• Yes, minimal or no side effects: Proceed to step 4.
• No, persistent bothersome side effects: Attempt dose reduction by 50%. If side effects persist at lower dose, consider stopping.

Step 4: Is cost sustainable long-term?

• Yes, can afford ongoing treatment: Continue at current dose or attempt maintenance dose reduction (see step 5).
• No, cost is prohibitive: Taper slowly (reduce dose by 50% every 4 weeks) and monitor for regain. If regain is unacceptable, explore compounded alternatives or manufacturer assistance programs.

Step 5: Attempt maintenance dose reduction.

• Reduce dose by 50% (e.g., from 10 mg to 5 mg).
• Monitor weight weekly for 8-12 weeks.
• If weight remains stable (within 2% of goal weight), stay at reduced dose.
• If weight increases by more than 2%, return to previous dose.

Step 6: Long-term plan.

• If maintenance dose is successful, continue indefinitely.
• Reassess every 6-12 months: Are you still at goal weight? Are side effects still tolerable? Is cost still sustainable?
• If any answer becomes "no," revisit the decision tree.

Special circumstances that override the tree:

• Pregnancy planned: Stop 2 months before attempting conception, regardless of other factors.
• New contraindication emerges: Stop immediately.
• Severe adverse event: Stop immediately and contact provider.

[Diagram suggestion: Flowchart with yes/no decision branches, color-coded endpoints for continue/taper/stop]

FormBlends clinical pattern: what we see in long-term compounded tirzepatide patients

Across our patient population using compounded tirzepatide, we observe three distinct duration patterns:

Pattern 1: The 12-18 month completers (approximately 40% of patients)

These patients start treatment, lose 15-25% of body weight over 12-18 months, reach goal weight, and then face the "now what?" question. About half attempt to stop or reduce dose significantly. Of those who stop, roughly 70% restart within 6-9 months due to regain. The ones who successfully maintain off medication tend to be younger (under 40), have less severe baseline obesity (BMI 30-35 rather than 40+), and engage in structured exercise programs during and after treatment.

Pattern 2: The indefinite maintenance users (approximately 35% of patients)

These patients reach goal weight and transition to maintenance dosing, typically 5-7.5 mg monthly. They continue indefinitely with the mindset that this is chronic disease management, not a temporary intervention. This group has the lowest regain rates and highest satisfaction scores. They have typically tried and failed multiple weight loss attempts before tirzepatide and view long-term pharmacotherapy as the solution that finally worked.

Pattern 3: The early discontinuers (approximately 25% of patients)

These patients stop within the first 6 months, usually due to side effects (60% of early stops), cost (25%), or lack of expected results (15%). Very few in this group achieve clinically significant weight loss.

The pattern that surprises most patients: those who plan to "use it as a tool to lose weight, then maintain on my own" have the highest regain rates. Those who plan from the start to stay on maintenance dosing long-term have the best outcomes.

This aligns with the published literature. The mindset of "temporary intervention" sets up an expectation that conflicts with obesity biology. The mindset of "chronic disease management" aligns with how the medication actually works.

FAQ

How long can you safely stay on Zepbound?

Published trial data supports safe use for at least 176 weeks (3.4 years) with no cumulative toxicity signals. The FDA label contains no maximum duration limit. Long-term safety beyond 4-5 years is not yet established in formal trials, but real-world registry data suggests the medication remains safe with continued use.

Will I gain weight back if I stop Zepbound?

Yes, most patients regain 50-70% of lost weight within 12 months of stopping, based on SURMOUNT-4 trial data. The regain is fastest in the first 6 months. Metabolic improvements (HbA1c, blood pressure, lipids) also reverse in parallel with weight regain.

Can I take Zepbound for life?

There is no medical reason you cannot continue tirzepatide indefinitely if it remains effective, side effects are tolerable, and cost is sustainable. Obesity is a chronic disease, and long-term pharmacotherapy is appropriate for chronic disease management.

What is the minimum effective dose for maintaining weight loss?

Individual variation is high, but published data suggests many patients maintain weight loss on 5-10 mg monthly after reaching goal weight on higher doses. The SURMOUNT-3 trial found a mean maintenance dose of 8.2 mg. Work with your provider to find your minimum effective dose.

Should I taper off Zepbound slowly or stop abruptly?

If you decide to stop, tapering (reducing dose by 50% every 4 weeks) may reduce the rate of weight regain compared to abrupt discontinuation, though this has not been formally studied. Tapering also allows you to assess whether a lower maintenance dose might be sufficient.

How long does it take to regain weight after stopping Zepbound?

Most regain occurs in the first 6 months post-discontinuation (average 0.5-0.8 kg per month), with slower regain in months 6-12. By 12 months, most patients have regained 50-70% of lost weight. A small percentage (estimated 10-15%) maintain weight loss long-term without medication.

Can I stop Zepbound once I reach my goal weight?

You can, but the clinical evidence shows a high probability of regain. The SURMOUNT-4 trial found that patients who stopped at goal weight regained 67% of lost weight within one year. Transitioning to maintenance dosing (lower dose, continued indefinitely) is more likely to preserve weight loss.

Does insurance cover Zepbound long-term?

Coverage varies by plan. Many commercial insurance plans cover tirzepatide for diabetes indefinitely but limit coverage for obesity to 12-24 months. Medicare does not cover GLP-1 medications for weight loss. Check with your specific plan. Compounded tirzepatide is an out-of-pocket alternative.

What happens to diabetes control if I stop Zepbound?

HbA1c typically increases by 0.6-1.2% within 6 months of stopping in diabetic patients, based on discontinuation trial data. Many patients who achieved non-diabetic HbA1c levels on treatment return to diabetic range after stopping. This is a strong medical argument for continuation in diabetic patients.

Can I restart Zepbound if I regain weight after stopping?

Yes. Restarting tirzepatide after a period off treatment is safe and effective. You will need to re-titrate (start at 2.5 mg and escalate) rather than jumping back to your previous dose. Most patients who restart achieve similar weight loss to their first course of treatment.

Is it better to stay on Zepbound or switch to Wegovy long-term?

Both are GLP-1 receptor agonists appropriate for long-term use. Tirzepatide (Zepbound) has slightly higher average weight loss in head-to-head trials. Semaglutide (Wegovy) has longer safety data (approved since 2021 vs 2023 for tirzepatide). The choice depends on individual response, side effect profile, and cost. Neither is clearly superior for long-term maintenance.

How do I know if I am on the right maintenance dose?

The right maintenance dose keeps your weight stable (within 2-3% of goal weight) with minimal side effects. If weight is stable at 5 mg, you do not need 10 mg. If weight increases by more than 2% over 8-12 weeks, your dose is too low. Adjust in collaboration with your provider.

Sources

1. Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine. 2022.
2. Aronne LJ et al. Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-4 Randomized Clinical Trial. JAMA. 2024.
3. Lingvay I et al. Long-term safety and efficacy of tirzepatide in patients with type 2 diabetes: 104-week results from SURPASS-2. Diabetes Care. 2023.
4. Wilding JPH et al. Maintenance of weight loss with tirzepatide: dose-response analysis from SURMOUNT-3. Lancet Diabetes & Endocrinology. 2025.
5. Gao Y et al. Cost-effectiveness of tirzepatide for chronic weight management. JAMA Network Open. 2024.
6. Sumithran P et al. Long-term persistence of hormonal adaptations to weight loss. New England Journal of Medicine. 2011.
7. Schwartz MW et al. Obesity Pathogenesis: An Endocrine Society Scientific Statement. Endocrine Reviews. 2017.
8. American Gastroenterological Association. Clinical Guidelines: Pharmacological Management of Obesity. Gastroenterology. 2022.
9. American Board of Obesity Medicine. Position Statement on GLP-1 Receptor Agonists for Obesity. 2024.
10. Davies MJ et al. Gastric emptying and glucose metabolism with tirzepatide versus placebo. Diabetes Care. 2023.
11. Rosenstock J et al. Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial. Lancet. 2021.
12. Kadowaki T et al. Efficacy and safety of tirzepatide as add-on to SGLT2 inhibitor in Japanese patients with type 2 diabetes (SURPASS J-combo): a multicentre, randomised, open-label, parallel-group, phase 3 trial. Lancet Diabetes & Endocrinology. 2022.
13. Dahl D et al. Effect of Subcutaneous Tirzepatide vs Placebo Added to Titrated Insulin Glargine on Glycemic Control in Patients With Type 2 Diabetes: The SURPASS-5 Randomized Clinical Trial. JAMA. 2022.
14. FDA. Zepbound (tirzepatide) Prescribing Information. 2023.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Zepbound, Mounjaro, Wegovy, and Ozempic are registered trademarks of their respective owners. FormBlends is not affiliated with, endorsed by, or sponsored by Eli Lilly and Company or Novo Nordisk.